Elsevier Buys Aureus Sciences to Tap Into Medicinal Chemistry Market | GenomeWeb

With its acquisition of Aureus Sciences, Elsevier is hoping to expand its suite of solutions for the drug discovery and development market into medicinal chemistry, where the company says there is a demand for high-quality data from pharmaceutical and biotechnology companies.

Elsevier purchased the privately-held French company this week for an undisclosed amount. Under its new ownership, Aureus Sciences will be part of Elsevier’s science and technology division.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions.